<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004748</url>
  </required_header>
  <id_info>
    <org_study_id>199/11664</org_study_id>
    <secondary_id>NEMCH-454</secondary_id>
    <nct_id>NCT00004748</nct_id>
  </id_info>
  <brief_title>Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis</brief_title>
  <official_title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Compare the efficacy of low-dose oral pulse methotrexate (MTX) and ursodiol versus
      colchicine and ursodiol in patients with primary biliary cirrhosis (PBC).

      II. Determine the optimum dose and duration of MTX treatment.

      III. Investigate the role of fibrogenic cytokines (FC) in PBC pathogenesis and the effect of
      treatment on FC production.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:

      This is a randomized, double-blind study. Patients are stratified by prior/concurrent medical
      management.

      Patients in the first group are treated with oral methotrexate 3 times a week and a daily
      oral placebo.

      Patients in the second group are treated with daily oral colchicine and an oral placebo 3
      times a week.

      Therapy continues for 10 years. Beginning year 2, daily oral ursodiol is administered to all
      patients. Patients with disease progression are crossed to the alternate group or undergo
      liver transplantation if clinically indicated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1989</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>90</enrollment>
  <condition>Liver Cirrhosis, Biliary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colchicine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ursodiol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Biopsy proven primary biliary cirrhosis (PBC); Disproportionate
        increase in alkaline phosphatase; Positive antimitochondrial antibody test OR Symptoms
        consistent with PBC, e.g.: pruritus, fatigue, malaise, jaundice, elevated bilirubin

        No clinically advanced PBC, i.e.: bilirubin greater than 10 mg/dL or albumin less than 2.5
        g/dL, determined by 2 analyses 10 weeks apart; bleeding esophageal varices or congestive
        gastropathy; chronic hepatic encephalopathy; chronic ascites

        --Prior/Concurrent Therapy-- No concurrent drugs associated with chronic liver disease

        --Patient Characteristics--

        Hematopoietic: WBC at least 2500 Platelets at least 100,000 (unless due to hypersplenism);
        Hematocrit at least 30%

        Renal: No renal disease that could cause liver dysfunction

        Other: No history of alcohol abuse; No other medical illness that might cause liver
        dysfunction, e.g., severe cardiac failure; No pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marshall M. Kaplan</last_name>
    <role>Study Chair</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>cirrhosis</keyword>
  <keyword>gastrointestinal disorders</keyword>
  <keyword>primary biliary cirrhosis</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

